Posts Tagged ‘obesity’

When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits. New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on […]

Metabolic and bariatric surgery in 2026 faces a strategic fork in the road. On one path we insist that surgery as the best option for weight loss – full stop. The other positions surgery as an essential tool for achieving optimal health in people living with obesity. How we choose to frame the value of […]

At the same time a daily tablet of an advanced obesity medicine is capturing much attention, two new monthly obesity medicines are advancing. The first, Maritide, is something we’ve been following for a while now. Amgen provided an update yesterday with their latest quarterly briefing on business results. The second is the fruit of a […]

If you were confused this week by headlines proclaiming that “nearly half of Americans will have obesity by 2035,” don’t feel bad. It means you are paying attention. Because this proclamation flies in the face of headlines from last year telling us obesity rates are declining in the U.S. So what gives? The New Research […]

Good luck if you want to make sense of headlines about health insurance and coverage trends for GLP-1 medicines. Peruse the headlines and you can find just about any narrative you want. “Rising health premiums push more small business to drop coverage,” according to Inc. “Employers are opting out of covering GLP-1s,” claims Hines, a […]

We are in the midst of what used to be known as diet and weight loss season. And now the Super Bowl is coming up. Instead of diet ads this year, our video feeds are full of ads for telehealth and GLP-1s. Some of them are annoying. But when Serena Williams comes on screen to […]

Yesterday, Roche announced topline results from a phase two study of a new injectable dual agonist medicine for obesity. The drug, CT-388, delivered a reduction in body weight of 22.5% after 48 weeks at the highest dose tested (24 mg). Placebo-subtracted weight loss was 18.3% and at 48 weeks, patients taking the drug were still […]

Observational studies have suggested for some time that obesity might raise the risk of dementia for a person with obesity. But observational studies have limitations. They can suggest a hypothesis. Not prove causality. So the news of evidence from a Mendelian randomization study that obesity can cause vascular dementia is important. Methods and Findings This […]

Reporting for the Washington Post, Daniel Gilbert tells us “the next frontier in weight-loss drugs is one-time gene therapy.” Setting aside his misuse of the “weight-loss” misnomer, should we take him seriously? How much can we expect from gene-based therapies for obesity? Scientifically Substantial The body of peer-reviewed evidence for genetic therapies in obesity is […]

Increasingly, it looks like calorie counting is dead. Remember 100-calorie snack packages? They came and went early in this millenium. They were the snack food industry response to then President George W. Bush pushing against a rising tide of obesity. Back then, obesity experts speculated that those packs “might be one potentially successful approach to […]